[Electrophysiological mechanisms of the effect of allapinin in patients with paroxysmal supraventricular tachycardia].
An intracardiac electrophysiological study was undertaken to examine 15 patients with paroxysmal supraventricular tachycardias. Allapinin intravenously given in a dose of 0.4 mg/kg, was tested for effects. The agent was demonstrated to cause a substantial inhibition of rapid retrograde pathway function in atrioventricular nodal tachycardia and abnormal antero- and retrograde pathway function. This is the major aspect of the drug's action that prevents the development of episodes of paroxysmal supraventricular tachycardias. The agent fails to virtually affect the function of the atrioventricular node in the anterograde direction in the two types of the tachycardia. Thus, allapinin has the mechanism of action that is typical of quinidine-like drugs used in supraventricular tachycardias.
Sokolov
S F
SF
Golitsyn
S P
SP
Manakhov
V I
VI
Zagraĭ
A A
AA
Bankuzov
V A
VA
Smetnev
A S
AS
D000157:Aconitine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D000328:Adult; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001283:Atrioventricular Node / Q000187:drug effects* / Q000503:physiopathology; D002304:Cardiac Pacing, Artificial; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D013611:Tachycardia, Atrioventricular Nodal Reentry / Q000503:physiopathology* / Q000517:prevention & control; D013614:Tachycardia, Paroxysmal / Q000503:physiopathology* / Q000517:prevention & control
D000889:Anti-Arrhythmia Agents; C051402:allapinin; D000157:Aconitine
Elektrofiziologicheskie mekhanizmy deĭstviia allapinina u bol'nykh s paroksizmal'nymi nadzheludochkovymi takhikardiiami.